---
title: "Hanx Biopharmaceuticals Appoints Xiao Jieyu as Executive Director and CFO"
description: "Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has appointed Ms. Xiao Jieyu as Executive Director and CFO, effective February 8, 2026. The company also announced the resignation of its joint company secreta"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274814638.md"
published_at: "2026-02-04T12:44:58.000Z"
---

# Hanx Biopharmaceuticals Appoints Xiao Jieyu as Executive Director and CFO

> Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has appointed Ms. Xiao Jieyu as Executive Director and CFO, effective February 8, 2026. The company also announced the resignation of its joint company secretary, CFO, secretary of the board, and vice general manager, alongside the appointment of a new CFO and secretary of the board.

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. announced several management changes, including the re-designation of Ms. Xiao Jieyu from non-executive director to executive director effective 8 February 2026. The company also announced the resignation of its joint company secretary, chief financial officer, secretary of the board, and vice general manager, as well as the appointment of a new chief financial officer and secretary of the board. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260204-12014766), on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [03378.HK - HANXBIO-B](https://longbridge.com/en/quote/03378.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hanx Biopharmaceuticals Files Director List with HKEX | Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has submitted an updated director list to the Hong Kong Stock Exchange. The Boa | [Link](https://longbridge.com/en/news/275224008.md) |
| Hanx Biopharmaceuticals Sets Out Board and Committee Structure | Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has announced its board composition, led by chairman Dr. Zhang Faming, includin | [Link](https://longbridge.com/en/news/275228301.md) |
| Shootin' the Bull about wave 5 of 5 of B | Shootin' the Bull about wave 5 of 5 of B | [Link](https://longbridge.com/en/news/276266924.md) |
| NVIDIA’s 13F Bombshell: A New AI Power Trio Emerges | NVIDIA's Q4 2025 13F filing reveals significant shifts in its public equity portfolio, adding Intel, Synopsys, and Nokia | [Link](https://longbridge.com/en/news/276480737.md) |
| Assessing NCC (OM:NCC B) Valuation After New SEK180 Million Road Contracts In Norway | NCC (OM:NCC B) has secured two contracts worth SEK 180 million for road work in Norway, set to be booked in Q1 2026. Cur | [Link](https://longbridge.com/en/news/276548893.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.